Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study, Respir Med. juillet, vol.107, issue.7, pp.1101-1112, 2013. ,
Clinical and economic burden of community-acquired pneumonia among adults in Europe, Thorax. 1 janv, vol.67, issue.1, pp.71-80, 2012. ,
The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis, Eur J Clin Microbiol Infect Dis. 14 déc, vol.32, issue.3, pp.305-321, 2012. ,
, Données épidémiologiques / Infections à pneumocoque / Maladies à prévention vaccinale / Maladies infectieuses / Dossiers thématiques / Accueil
,
, Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Antibody response to pneumococcal vaccine in children aged 5 to 15 years, Am J Dis Child. févr, vol.140, issue.2, pp.135-143, 1986. ,
DOI : 10.1001/archpedi.1986.02140160053031
Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?, The Lancet Infectious Diseases. 1 juill, vol.8, issue.7, pp.405-411, 2008. ,
DOI : 10.1016/s1473-3099(08)70134-8
The role of Pneumococcal vaccine, Pulm Pharmacol Ther. août, vol.21, issue.4, pp.608-623, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00499155
23-valent pneumococcal polysaccharide vaccine : WHO position paper = Vaccin antipneumococcique polyosidique 23-valent : Note de synthèse de l'OMS. Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire, vol.83, pp.373-84, 2008. ,
Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine, J Infect Dis. mars, vol.165, issue.3, pp.553-559, 1992. ,
Impact of vaccination on invasive pneumococcal disease in adults with focus on the immunosuppressed, J Infect, vol.71, issue.4, pp.422-429, 2015. ,
Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more p, p.60 ,
, than 5 years does not affect the immunogenicity and safety in the Japanese elderly, Hum Vaccin Immunother. 26 mars, pp.1-8, 2018.
Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions, Rev Epidemiol Sante Publique, vol.33, issue.6, pp.437-481, 1985. ,
Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies, PLoS ONE, vol.12, issue.5, p.177985, 2017. ,
The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis, Vaccine. 18 mars, vol.34, issue.13, pp.1540-50, 2016. ,
Clinical and Serologic Response to the 23-valent Polysaccharide Pneumococcal Vaccine in Children and Teens with Recurrent Upper Respiratory Tract Infections and Selective Antibody Deficiency, Pediatr Infect Dis J. févr, vol.35, issue.2, pp.205-213, 2016. ,
,
, Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review, BMC Infect Dis, vol.25, issue.1, p.711, 2016.
,
, Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults, N Engl J Med. 19 mars, vol.372, issue.12, pp.1114-1139, 2015.
Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States, Antimicrob Agents Chemother, vol.58, issue.11, pp.6484-6493, 2014. ,
Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study, Lancet Respir Med, vol.5, issue.8, pp.648-56, 2017. ,
,
, Pneumococcal Conjugated Vaccine Reduces the High Mortality for CommunityAcquired Pneumonia in the Elderly: an Italian Regional Experience, PLoS ONE, vol.11, issue.11, p.166637, 2016.
Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Pediatr Infect Dis J. nov, vol.34, issue.11, pp.1168-74, 2015. ,
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia, J Infect Dis, vol.198, issue.7, pp.1019-1046, 2008. ,
Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study, PLoS ONE, vol.11, issue.6, p.156523, 2016. ,
Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses, Vaccine, vol.19, issue.33, pp.3875-81, 2016. ,
Febrile Seizure Risk After Vaccination in Children 6 to 23 Months, Pediatrics. juill, vol.138, issue.1, 2016. ,
, Bilan français des effets indésirables du vaccin Prévenar 13®, vol.24, pp.439-483, 2017.
Epidémiologie de la résistance aux antibiotiques des pneumocoques, Rev Med Suisse, 2004. ,
,
, Vaccination contre les infections invasives à pneumocoque avec le vaccin pneumococcique conjuqué 13-valent, Rapport [Internet] HCSP -Haut Conseil de Santé Publique, 2009.
,
Rapport d'activité 2016. Cent Natl Réf Pneumoc Paris ,
Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Pediatr Infect Dis J. nov, vol.34, issue.11, pp.1168-74, 2015. ,
, European Centre for Disease Prevention and Control, 2017.
,
, Infections à pneumocoque : recommandations vaccinales pour les adultes [Internet] HCSP -Haut Conseil de Santé Publique, 2017.
Le médecin généraliste picard face aux vaccinations en, 2016. ,
, Pneumocoque / Données / Couverture vaccinale / Maladies à prévention vaccinale / Maladies infectieuses / Dossiers thématiques / Accueil
,
Attitudes et freins du médecin généraliste à propos de la vaccination antipneumococcique des patients immunodéprimés: enquête qualitative réalisée auprès de 13 médecins généralistes de la Somme, 2017. ,
Evaluation et pratique des médecins généralistes à propos de la vaccination anti-pneumococcique à 23 valences chez l'adulte en Picardie, 2013. ,
Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis, Hum Vaccin Immunother. 12 févr, pp.1-7, 2018. ,
Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older, Vaccine, vol.03, issue.19, pp.2510-2532, 2018. ,
Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands, PLoS ONE, vol.13, issue.2, p.192640, 2018. ,
A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan, J Med Econ. 3 mai, pp.1-11, 2018. ,
Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control, BMC Med, vol.08, issue.1, p.13, 2018. ,
Analysis of the effectiveness and long-term results of formation of adaptive immunity in the use of various medications and vaccination schemes against pneumococcal infection ,
, Ter Arkh, vol.89, issue.12, pp.165-74, 2017.
Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease, AFP. 1 avr, vol.97, issue.7, pp.463-467, 2018. ,
, Vaccinations : attitudes et pratiques des médecins généralistes ÉTUDES et RÉSULTATS n° 910 -mars 2015 [Internet] Riposa C. mars 2015
Enquête sur les attitudes vaccinales des pneumologues dans la BPCO. Focus sur la vaccination antipneumococcique, Revue des Maladies Respiratoires. 1 janv, vol.35, p.198, 2018. ,
DOI : 10.1016/j.rmr.2017.10.449
Impact du conseil hospitalier sur la vaccination antipneumococcique des adultes à risques par leurs médecins généralistes, pp.2011-50 ,
Pratique et suivi des modalités de la vaccination anti pneumococcique par les médecins généralistes chez les adultes depuis la mise à jour du calendrier vaccinal en mai, 2012. ,
Creation, characterization, and assignment of opsonic values for a new pneumococcal OPA calibration serum panel (Ewha QC sera panel A) for 13 serotypes, Medicine (Baltimore). avr, vol.97, issue.17, p.567, 2018. ,